Last mentioned: Feb 27, 2026
Clinical Catalyst
Anticipated data readouts for sevasemten in Becker Muscular Dystrophy trials.
52-Week High
EWTX stock reaches a new yearly peak amid clinical pipeline optimism.
Analyst Upgrade
Wall Street Zen raises Edgewise Therapeutics to a 'Hold' rating.
Edgewise Therapeutics and Ericsson have both breached 52-week price peaks, signaling robust investor confidence in biotech innovation and telecom infrastructure recovery. While Edgewise benefits from clinical momentum in muscle disease treatments, Ericsson's ascent reflects a stabilized global 5G landscape and a strategic pivot toward AI-native networking.
Edgewise Therapeutics (NASDAQ: EWTX) has reached a new 52-week high, reflecting growing investor confidence in its clinical-stage pipeline for rare muscle and cardiac diseases. The surge follows recent analyst upgrades and positive sentiment surrounding its lead candidates, sevasemten and EDG-7500.